ArticleNature communications2021
Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Knowledge landscape of Treg research in breast cancer: a bibliometric and visual analysis.Frontiers in oncology · 2024Pooled it
- T Cell Thoughts.Immunological reviews · 2026Review
- Molecular heterogeneity and clonal origin of CCR8Nature communications · 2026Article
- An 8-gene diabetes-related signature predicts survival and immunotherapy response in breast cancer.Clinics (Sao Paulo, Brazil) · 2026Article
- HarveST uses a heterogeneous graph learning framework to reveal spatial transcriptomics patterns.Communications biology · 2026Article
- Specific depletion of TIGITJournal for immunotherapy of cancer · 2026Article
- Decoding the tumor microenvironment of triple-negative breast cancer: from immune evasion to precision immunotherapy.Frontiers in immunology · 2026Review
- Article
- Immunological Landscape and Molecular Therapeutic Targets of the Tumor Microenvironment in Hepatocellular Carcinoma.International journal of molecular sciences · 2025Review
- Immunometabolism of regulatory T cells in cancer.Oncogene · 2025Review
- Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39.The Journal of experimental medicine · 2025Article
- CD4Science advances · 2025Article
- Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer.Nature communications · 2024Article
- Defining Human Regulatory T Cells beyond FOXP3: The Need to Combine Phenotype with Function.Cells · 2024Review
- Selective targeting or reprogramming of intra-tumoral Tregs.Medical oncology (Northwood, London, England) · 2024Review
- Targeting T regulatory (TCancer drug resistance (Alhambra, Calif.) · 2024Review
- Article
- IL-2 and TCR stimulation induce expression and secretion of IL-32β by human T cells.Frontiers in immunology · 2024Article
- Evaluation of the Suppressive Capacity of Regulatory T Cells in Food Allergy Research.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor control.Cell reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 8 institutions in 4 countries.
Maria Xydia *RCI Regensburg Centre for Interventional Immunology, University and Department of Hematology/Oncology, University Medical Centre of Regensburg, Regensburg, Germany. Maria.Xydia@ukr.de.ORCID http://orcid.org/0000-0001-6057-5330
Raheleh Rahbari *The Cancer, Ageing and Somatic Mutation Program, Wellcome Sanger Institute, Hinxton, UK.ORCID http://orcid.org/0000-0002-1839-7785
Eliana Ruggiero *Translational Oncology Department, National Centre for Tumor Diseases and German Cancer Research Centre, Heidelberg, Germany.
Iain MacaulayThe Cancer, Ageing and Somatic Mutation Program, Wellcome Sanger Institute, Hinxton, UK.
Maxime TarabichiThe Cancer, Ageing and Somatic Mutation Program, Wellcome Sanger Institute, Hinxton, UK.
Robert LohmayerRCI Regensburg Centre for Interventional Immunology, University and Department of Hematology/Oncology, University Medical Centre of Regensburg, Regensburg, Germany.
Stefan WilkeningTranslational Oncology Department, National Centre for Tumor Diseases and German Cancer Research Centre, Heidelberg, Germany.
Tillmann MichelsRCI Regensburg Centre for Interventional Immunology, University and Department of Hematology/Oncology, University Medical Centre of Regensburg, Regensburg, Germany.ORCID http://orcid.org/0000-0003-2717-4214
Daniel BrownDepartment of Human Genetics, University of Leuven, KU Leuven, Leuven, Belgium.
Sebastiaan VanuytvenThe Francis Crick Institute, London, UK.
Svetlana MastitskayaMedical Oncology Department, National Centre for Tumor Diseases, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-4819-2908
Sean LaidlawThe Cancer, Ageing and Somatic Mutation Program, Wellcome Sanger Institute, Hinxton, UK.ORCID http://orcid.org/0000-0001-7658-1428
Niels GrabeMedical Oncology Department, National Centre for Tumor Diseases, Heidelberg, Germany.
Maria PritschTranslational Immunology Department, German Cancer Research Centre, Heidelberg, Germany.
Raffaele FronzaTranslational Oncology Department, National Centre for Tumor Diseases and German Cancer Research Centre, Heidelberg, Germany.
Klaus HexelFlow Cytometry Core Facility, German Cancer Research Centre, Heidelberg, Germany.
Steffen SchmittFlow Cytometry Core Facility, German Cancer Research Centre, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-7055-4656
Michael Müller-SteinhardtGerman Red Cross (DRK Blood Donation Service in Baden-Württemberg-Hessen) and Institute for Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Niels HalamaMedical Oncology Department, National Centre for Tumor Diseases, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-0344-6027
Christoph DomschkeDepartment of Gynecology and Obstetrics, University Hospital of Heidelberg, Heidelberg, Germany.
Manfred SchmidtTranslational Oncology Department, National Centre for Tumor Diseases and German Cancer Research Centre, Heidelberg, Germany.
Christof von KalleTranslational Oncology Department, National Centre for Tumor Diseases and German Cancer Research Centre, Heidelberg, Germany.
Florian SchützDepartment of Gynecology and Obstetrics, University Hospital of Heidelberg, Heidelberg, Germany.
Thierry VoetThe Cancer, Ageing and Somatic Mutation Program, Wellcome Sanger Institute, Hinxton, UK.
Philipp BeckhoveRCI Regensburg Centre for Interventional Immunology, University and Department of Hematology/Oncology, University Medical Centre of Regensburg, Regensburg, Germany. beckhove@rcii.de.ORCID http://orcid.org/0000-0002-0099-5576
German Cancer Research Center · DEHeidelberg University · DEWellcome Sanger Institute · GBThe Francis Crick Institute · GBUniversity Hospital Regensburg · DECharité - Universitätsmedizin Berlin · DENational Center for Tumor Diseases · DEWalter and Eliza Hall Institute of Medical Research · AU
Funding
Cancer Research UK 27114Cancer Research UK C66259/A27114Cancer Research UK FC001202Medical Research Council FC001202Medical Research Council MR/L016311/1Wellcome Trust FC001202
Abstract
Regulatory CD4
Indexed as
Antigens, NeoplasmBreast NeoplasmsCell Line, TumorCell ProliferationClone CellsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLymphocyte ActivationNeoplasm StagingReceptors, Antigen, T-CellSingle-Cell AnalysisTh1 CellsT-Lymphocytes, RegulatoryTranscriptomeAntigens, NeoplasmReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.